Targeting the C-Terminal Domain Small Phosphatase 1

The human C-terminal domain small phosphatase 1 (CTDSP1/SCP1) is a protein phosphatase with a conserved catalytic site of DXDXT/V. CTDSP1’s major activity has been identified as dephosphorylation of the 5th Ser residue of the tandem heptad repeat of the RNA polymerase II C-terminal domain (RNAP II CTD). It is also implicated in various pivotal biological activities, such as acting as a driving factor in repressor element 1 (RE-1)-silencing transcription factor (REST) complex, which silences the neuronal genes in non-neuronal cells, G1/S phase transition, and osteoblast differentiation. Recent findings have denoted that negative regulation of CTDSP1 results in suppression of cancer invasion in neuroglioma cells. Several researchers have focused on the development of regulating materials of CTDSP1, due to the significant roles it has in various biological activities. In this review, we focused on this emerging target and explored the biological significance, challenges, and opportunities in targeting CTDSP1 from a drug designing perspective.

[1]  F. Goldwasser,et al.  Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics , 2015, Expert opinion on investigational drugs.

[2]  O. Jänne,et al.  Small carboxyl‐terminal domain phosphatase 2 attenuates androgen‐dependent transcription , 2006, The EMBO journal.

[3]  Diane Joseph-McCarthy,et al.  Ensemble-Based Docking Using Biased Molecular Dynamics , 2014, J. Chem. Inf. Model..

[4]  Ivet Bahar,et al.  Pharmmaker: Pharmacophore modeling and hit identification based on druggability simulations , 2019, Protein science : a publication of the Protein Society.

[5]  D. Reinberg,et al.  FCP 1 , a Phosphatase Specific for the Heptapeptide Repeat of the Largest Subunit of RNA Polymerase II , Stimulates Transcription Elongation , 2002 .

[6]  Ruben Abagyan,et al.  Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach , 2017, Journal of Computer-Aided Molecular Design.

[7]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[8]  Claudio N. Cavasotto,et al.  Normal mode-based approaches in receptor ensemble docking. , 2012, Methods in molecular biology.

[9]  Anthony C. Bishop,et al.  Targeting a Cryptic Allosteric Site for Selective Inhibition of the Oncogenic Protein Tyrosine Phosphatase Shp2 , 2014, Biochemistry.

[10]  Pavan V. Payghan,et al.  Use of molecular dynamics simulations in structure-based drug discovery. , 2019, Current pharmaceutical design.

[11]  David S. Goodsell,et al.  Protein Flexibility in Virtual Screening: The BACE-1 Case Study , 2012, J. Chem. Inf. Model..

[12]  Qian Wu,et al.  Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway , 2020, Acta Pharmacologica Sinica.

[13]  P. Lijnzaad,et al.  FOXO target gene CTDSP2 regulates cell cycle progression through Ras and p21Cip1/Waf1 , 2015, The Biochemical journal.

[14]  Jessica Lynn Grey,et al.  Challenges and opportunities for new protein crystallization strategies in structure-based drug design , 2010, Expert opinion on drug discovery.

[15]  Julio Caballero,et al.  Is It Reliable to Use Common Molecular Docking Methods for Comparing the Binding Affinities of Enantiomer Pairs for Their Protein Target? , 2016, International journal of molecular sciences.

[16]  Yanli Wang,et al.  Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.

[17]  N. Subbarao,et al.  Allosteric inhibition of topoisomerase I by pinostrobin: Molecular docking, spectroscopic and topoisomerase I activity studies. , 2017, Journal of photochemistry and photobiology. B, Biology.

[18]  Wei Zhang,et al.  Identification of the Binding Site of an Allosteric Ligand Using STD‐NMR, Docking, and CORCEMA‐ST Calculations , 2013, ChemMedChem.

[19]  Yanjie Wei,et al.  DeepBindRG: a deep learning based method for estimating effective protein–ligand affinity , 2019, PeerJ.

[20]  A. Mbonye,et al.  Introducing rapid diagnostic tests for malaria into drug shops in Uganda: design and implementation of a cluster randomized trial , 2014, Trials.

[21]  A. Brivanlou,et al.  Dephosphorylation of the Linker Regions of Smad1 and Smad2/3 by Small C-terminal Domain Phosphatases Has Distinct Outcomes for Bone Morphogenetic Protein and Transforming Growth Factor-β Pathways* , 2006, Journal of Biological Chemistry.

[22]  Sina Shahbazmohamadi,et al.  Assemble-And-Match: A Novel Hybrid Tool for Enhancing Education and Research in Rational Structure Based Drug Design , 2018, Scientific Reports.

[23]  P. Lin,et al.  Functional characterization of small CTD phosphatases. , 2007, Methods in molecular biology.

[24]  J. Tuszynski,et al.  Software for molecular docking: a review , 2017, Biophysical Reviews.

[25]  Arthur Christopoulos,et al.  Allosteric targeting of receptor tyrosine kinases , 2014, Nature Biotechnology.

[26]  Li Li,et al.  Structure-Based Drug Design Strategies and Challenges. , 2018, Current topics in medicinal chemistry.

[27]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[28]  G. Stein,et al.  The role of Runx2 in facilitating autophagy in metastatic breast cancer cells , 2018, Journal of cellular physiology.

[29]  C. Lima,et al.  The structure of Fcp1, an essential RNA polymerase II CTD phosphatase. , 2008, Molecular cell.

[30]  Martin Zacharias,et al.  Monte Carlo replica‐exchange based ensemble docking of protein conformations , 2017, Proteins.

[31]  Mengang Xu,et al.  Utilizing Experimental Data for Reducing Ensemble Size in Flexible-Protein Docking , 2012, J. Chem. Inf. Model..

[32]  J. An,et al.  Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.

[33]  L. S. Churchman,et al.  The code and beyond: transcription regulation by the RNA polymerase II carboxy-terminal domain , 2017, Nature Reviews Molecular Cell Biology.

[34]  Y. Chuman,et al.  Identification of a Specific Inhibitor of Human Scp1 Phosphatase Using the Phosphorylation Mimic Phage Display Method , 2019, Catalysts.

[35]  L. Leibovici,et al.  Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. , 2009, Infectious disease clinics of North America.

[36]  B. Lakshmi,et al.  In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations , 2019, Journal of Molecular Modeling.

[37]  D. Grigoriadis,et al.  Drugability of Extracellular Targets: Discovery of Small Molecule Drugs Targeting Allosteric, Functional, and Subunit-Selective Sites on GPCRs and Ion Channels , 2009, Neuropsychopharmacology.

[38]  R. V. van Montfort,et al.  Structure-based drug design: aiming for a perfect fit , 2017, Essays in biochemistry.

[39]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[40]  Youngjun Kim Emerging Roles of CTD Phosphatases , 2017 .

[41]  Maria Laura Bolognesi,et al.  Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases. , 2019, Current topics in medicinal chemistry.

[42]  Ismail Erol,et al.  Identification of novel serotonin reuptake inhibitors targeting central and allosteric binding sites: A virtual screening and molecular dynamics simulations study. , 2017, Journal of molecular graphics & modelling.

[43]  D. Brömme,et al.  A composite docking approach for the identification and characterization of ectosteric inhibitors of cathepsin K , 2017, PloS one.

[44]  Olivier Sheik Amamuddy,et al.  Integrated Computational Approaches and Tools for Allosteric Drug Discovery , 2020, International journal of molecular sciences.

[45]  J. Pratap,et al.  Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells , 2014, Breast Cancer Research.

[46]  G. Keserű,et al.  Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery. , 2017, Current topics in medicinal chemistry.

[47]  J. Lorens,et al.  Cellular context–mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis , 2015, Molecular biology of the cell.

[48]  Maciej Majewski,et al.  Dynamic Undocking: A Novel Method for Structure-Based Drug Discovery. , 2018, Methods in molecular biology.

[49]  F. Robert,et al.  The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain. , 2016, Journal of molecular biology.

[50]  Shibo Jiang,et al.  From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain , 2016, Expert opinion on biological therapy.

[51]  Liang Weng,et al.  Angiogenesis effect of therapeutic ultrasound on HUVECs through activation of the PI3K-Akt-eNOS signal pathway. , 2015, American journal of translational research.

[52]  Eun Jeong Cho,et al.  Selective inactivation of a human neuronal silencing phosphatase by a small molecule inhibitor. , 2011, ACS chemical biology.

[53]  Woody Sherman,et al.  Improving database enrichment through ensemble docking , 2008, J. Comput. Aided Mol. Des..

[54]  Hwangseo Park,et al.  Two-track virtual screening approach to identify both competitive and allosteric inhibitors of human small C-terminal domain phosphatase 1 , 2017, Journal of Computer-Aided Molecular Design.

[55]  J. Greenblatt,et al.  FCP1, the RAP74-Interacting Subunit of a Human Protein Phosphatase That Dephosphorylates the Carboxyl-terminal Domain of RNA Polymerase IIO* , 1998, The Journal of Biological Chemistry.

[56]  David E. Clark,et al.  A comparison of heuristic search algorithms for molecular docking , 1997, J. Comput. Aided Mol. Des..

[57]  A. Sali,et al.  Structural genomics of protein phosphatases , 2007, Journal of Structural and Functional Genomics.

[58]  J. Dixon,et al.  A conserved phosphatase cascade that regulates nuclear membrane biogenesis , 2007, Proceedings of the National Academy of Sciences.

[59]  J. Tardif,et al.  Pharmacogenomics to Revive Drug Development in Cardiovascular Disease , 2016, Cardiovascular Drugs and Therapy.

[60]  Sangdun Choi,et al.  A Structure-Based Drug Discovery Paradigm , 2019, International journal of molecular sciences.

[61]  Kenneth M Merz,et al.  Molecular recognition and drug-lead identification: what can molecular simulations tell us? , 2010, Current medicinal chemistry.

[62]  Y. Li,et al.  Palmitoylated SCP1 is targeted to the plasma membrane and negatively regulates angiogenesis , 2017, eLife.

[63]  Jong-Bok Yoon,et al.  Solution Structure and Rpn1 Interaction of the UBL Domain of Human RNA Polymerase II C-Terminal Domain Phosphatase , 2013, PloS one.

[64]  Geng Wu,et al.  ASD: a comprehensive database of allosteric proteins and modulators , 2010, Nucleic Acids Res..

[65]  A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion , 2012, Breast Cancer Research.

[66]  Z. Oltvai,et al.  Identification of novel bacterial histidine biosynthesis inhibitors using docking, ensemble rescoring, and whole-cell assays. , 2010, Bioorganic & medicinal chemistry.

[67]  I. Ghosh,et al.  New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. , 2012, Current pharmaceutical design.

[68]  Shigenori Tanaka,et al.  Cosolvent-Based Molecular Dynamics for Ensemble Docking: Practical Method for Generating Druggable Protein Conformations , 2017, J. Chem. Inf. Model..

[69]  Ruben Abagyan,et al.  Recipes for the Selection of Experimental Protein Conformations for Virtual Screening , 2010, J. Chem. Inf. Model..

[70]  Jia Cao,et al.  Overexpression of miR-26b-5p regulates the cell cycle by targeting CCND2 in GC-2 cells under exposure to extremely low frequency electromagnetic fields , 2016, Cell cycle.

[71]  Tina Ritschel,et al.  Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery , 2018 .

[72]  Ruth Huey,et al.  Computational protein–ligand docking and virtual drug screening with the AutoDock suite , 2016, Nature Protocols.

[73]  M. Barahona,et al.  Prediction of allosteric sites and mediating interactions through bond-to-bond propensities , 2016, Nature Communications.

[74]  Sally R. Ellingson,et al.  Ensemble-based docking: From hit discovery to metabolism and toxicity predictions. , 2016, Bioorganic & medicinal chemistry.

[75]  F. Jiang,et al.  Phosphatase activity of small C-terminal domain phosphatase 1 (SCP1) controls the stability of the key neuronal regulator RE1-silencing transcription factor (REST) , 2018, The Journal of Biological Chemistry.

[76]  J. Pratap,et al.  ­­Role of Runx2 in Crosstalk Between Mek/Erk and PI3K/Akt Signaling in MCF‐10A Cells , 2014, Journal of cellular biochemistry.

[77]  Yan Wang,et al.  The novel targets of DL-3-n-butylphthalide predicted by similarity ensemble approach in combination with molecular docking study. , 2017, Quantitative imaging in medicine and surgery.

[78]  Xia Lin,et al.  The Small C-terminal Domain Phosphatase 1 Inhibits Cancer Cell Migration and Invasion by Dephosphorylating Ser(P)68-Twist1 to Accelerate Twist1 Protein Degradation* , 2016, The Journal of Biological Chemistry.

[79]  Jingliang Cheng,et al.  Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition , 2015, Oncotarget.

[80]  C. Lima,et al.  Genetic and structural analysis of the essential fission yeast RNA polymerase II CTD phosphatase Fcp1 , 2015, RNA.

[81]  Pedro H M Torres,et al.  Key Topics in Molecular Docking for Drug Design , 2019, International journal of molecular sciences.

[82]  Lei Xie,et al.  Structure-based systems biology for analyzing off-target binding. , 2011, Current opinion in structural biology.

[83]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[84]  Stefan Paula,et al.  Comparison of current docking tools for the simulation of inhibitor binding by the transmembrane domain of the sarco/endoplasmic reticulum calcium ATPase. , 2010, Biophysical chemistry.

[85]  Jin Zhang,et al.  Toward a Benchmarking Data Set Able to Evaluate Ligand- and Structure-based Virtual Screening Using Public HTS Data , 2015, J. Chem. Inf. Model..

[86]  R. Gelber,et al.  First--select the target: better choice of adjuvant treatments for breast cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  Richard D. Taylor,et al.  Modeling water molecules in protein-ligand docking using GOLD. , 2005, Journal of medicinal chemistry.

[88]  Yan Zhang,et al.  Determinants for dephosphorylation of the RNA polymerase II C‐terminal domain by Scp1 , 2006, Molecular cell.

[89]  Louis-Philippe Morency,et al.  Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects , 2017, BMC Pharmacology and Toxicology.

[90]  T. Blundell,et al.  Probing the druggability of protein-protein interactions: targeting the Notch1 receptor ankyrin domain using a fragment-based approach. , 2011, Biochemical Society transactions.

[91]  J. Bolla,et al.  The Research of New Inhibitors of Bacterial Methionine Aminopeptidase by Structure Based Virtual Screening Approach of ZINC DATABASE and In Vitro Validation , 2020 .

[92]  Liliane Mouawad,et al.  vSDC: a method to improve early recognition in virtual screening when limited experimental resources are available , 2016, Journal of Cheminformatics.

[93]  I. Ghosh,et al.  Molecules that Target beta‐Amyloid , 2007, ChemMedChem.

[94]  Andrej Sali,et al.  Virtual ligand screening against comparative protein structure models. , 2012, Methods in molecular biology.

[95]  A. Bonen,et al.  Fatty acid transport and transporters in muscle are critically regulated by Akt2 , 2015, FEBS letters.

[96]  P. Lin,et al.  A Novel RNA Polymerase II C-terminal Domain Phosphatase That Preferentially Dephosphorylates Serine 5* , 2003, Journal of Biological Chemistry.

[97]  F. Cheng,et al.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.

[98]  Matthew L. Danielson,et al.  Computer-aided drug design platform using PyMOL , 2011, J. Comput. Aided Mol. Des..

[99]  M. Mezei,et al.  Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.

[100]  J. Pratap,et al.  Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis , 2016, Oncogene.

[101]  Yan Xia,et al.  Predicting protein targets for drug-like compounds using transcriptomics , 2018, bioRxiv.

[102]  Docking to large allosteric binding sites on protein surfaces. , 2010, Advances in experimental medicine and biology.

[103]  B. Nilius,et al.  Pharmacology of Vanilloid Transient Receptor Potential Cation Channels , 2009, Molecular Pharmacology.

[104]  Anton Meinhart,et al.  Structure and mechanism of RNA polymerase II CTD phosphatases. , 2004, Molecular cell.

[105]  J. Fraczek,et al.  Toxicological and metabolic considerations for histone deacetylase inhibitors , 2013, Expert opinion on drug metabolism & toxicology.

[106]  E. Raymond,et al.  Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. , 2010, Endocrinology and metabolism clinics of North America.

[107]  Sally R. Ellingson,et al.  Multi-conformer ensemble docking to difficult protein targets. , 2015, The journal of physical chemistry. B.

[108]  Wen Peng,et al.  Targeting cancer stem cell pathways for cancer therapy , 2020, Signal Transduction and Targeted Therapy.

[109]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[110]  Wolfgang Jahnke,et al.  Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. , 2014, Future medicinal chemistry.

[111]  J. Tainer,et al.  Screening a peptidyl database for potential ligands to proteins with side‐chain flexibility , 1998, Proteins.

[112]  Young Jun Kim,et al.  Structure-Based Virtual Screening of Protein Tyrosine Phosphatase Inhibitors: Significance, Challenges, and Solutions. , 2017, Journal of microbiology and biotechnology.

[113]  G. Keserű,et al.  Ensemble docking-based virtual screening yields novel spirocyclic JAK1 inhibitors. , 2016, Journal of molecular graphics & modelling.

[114]  Young Jun Kim,et al.  Peripheral Inhibition of Small C‐Terminal Domain Phosphatase 1 With Napthoquinone Analogs , 2020 .

[115]  Hackyoung Kim,et al.  The diverse roles of RNA polymerase II C-terminal domain phosphatase SCP1 , 2014, BMB reports.

[116]  T. Klabunde,et al.  Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.

[117]  X. Zou,et al.  Ensemble docking of multiple protein structures: Considering protein structural variations in molecular docking , 2006, Proteins.

[118]  S. Pfaff,et al.  Small CTD Phosphatases Function in Silencing Neuronal Gene Expression , 2005, Science.

[119]  Andrew J. Doig,et al.  Properties of Protein Drug Target Classes , 2015, PloS one.

[120]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[121]  Ruben Abagyan,et al.  Structure-Based Ligand Discovery Targeting Orthosteric and Allosteric Pockets of Dopamine Receptors , 2013, Molecular Pharmacology.

[122]  S. Singh,et al.  Identification of Dual negative allosteric modulators of Group I mGluR family: A shape based screening, ADME Prediction, Induced Fit Docking and Molecular Dynamics approach against Neurodegenerative Diseases. , 2019, Current topics in medicinal chemistry.

[123]  Q. Wei,et al.  Polymorphisms in the AKT1 and AKT2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population , 2016, Journal of cellular and molecular medicine.

[124]  Yuko Okamoto,et al.  Ligand docking simulations by generalized-ensemble algorithms. , 2013, Advances in protein chemistry and structural biology.

[125]  Glen E Kellogg,et al.  How to deal with low-resolution target structures: using SAR, ensemble docking, hydropathic analysis, and 3D-QSAR to definitively map the αβ-tubulin colchicine site. , 2013, Journal of medicinal chemistry.

[126]  A. Mandell,et al.  Designing allosteric peptide ligands targeting a globular protein. , 2007, Biopolymers.

[127]  G. Terstappen,et al.  How to Achieve Confidence in Drug Discovery and Development: Managing Risk (from a Reductionist to a Holistic Approach) , 2009, ChemMedChem.

[128]  M. A. Afanasyeva,et al.  Tumor suppressor properties of the small C-terminal domain phosphatases in non-small cell lung cancer , 2019, Bioscience reports.

[129]  Y. Bahk,et al.  A study of substrate specificity for a CTD phosphatase, SCP1, by proteomic screening of binding partners. , 2014, Biochemical and biophysical research communications.

[130]  Benjamin P. Cossins,et al.  Small Molecule Targeting of Protein–Protein Interactions through Allosteric Modulation of Dynamics , 2015, Molecules.

[131]  C L Verlinde,et al.  Structure-based drug design: progress, results and challenges. , 1994, Structure.

[132]  Jonathan W. Essex,et al.  Ensemble Docking into Multiple Crystallographically Derived Protein Structures: An Evaluation Based on the Statistical Analysis of Enrichments , 2010, J. Chem. Inf. Model..

[133]  Ruben Abagyan,et al.  Docking and scoring with ICM: the benchmarking results and strategies for improvement , 2012, Journal of Computer-Aided Molecular Design.

[134]  Yingkai Zhang,et al.  Computational Strategy for Bound State Structure Prediction in Structure-Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitors , 2018, J. Chem. Inf. Model..

[135]  Mauricio O. Carneiro,et al.  A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk , 2017, Diabetes.

[136]  J. Kim,et al.  Akt regulates Progesterone Receptor B dependent transcription and angiogenesis in endometrial cancer cells , 2016, Oncogene.

[137]  Jian Wang,et al.  Computational investigation of imidazopyridine analogs as protein kinase B (Akt1) allosteric inhibitors by using 3D-QSAR, molecular docking and molecular dynamics simulations , 2019, Journal of biomolecular structure & dynamics.

[138]  J. Dixon,et al.  Structural and functional analysis of the phosphoryl transfer reaction mediated by the human small C‐terminal domain phosphatase, Scp1 , 2010, Protein science : a publication of the Protein Society.

[139]  M. Tiwari,et al.  Variable selection based QSAR modeling on Bisphenylbenzimidazole as Inhibitor of HIV-1 reverse transcriptase. , 2013, Medicinal chemistry (Shariqah (United Arab Emirates)).

[140]  W. Wang,et al.  SCP1 regulates c-Myc stability and functions through dephosphorylating c-Myc Ser62 , 2016, Oncogene.

[141]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[142]  Gail Mandel,et al.  C-terminal domain small phosphatase 1 and MAP kinase reciprocally control REST stability and neuronal differentiation , 2014, Proceedings of the National Academy of Sciences.

[143]  M. Tang,et al.  SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling. , 2014, Cancer research.

[144]  Svetlana A. Varentsova,et al.  Essential Limitations of the Standard THz TDS Method for Substance Detection and Identification and a Way of Overcoming Them , 2016, Sensors.

[145]  Alexandre M J J Bonvin,et al.  Information-Driven, Ensemble Flexible Peptide Docking Using HADDOCK. , 2017, Methods in molecular biology.

[146]  X. Barril,et al.  Virtual screening in structure-based drug discovery. , 2004, Mini reviews in medicinal chemistry.

[147]  Shaoyong Lu,et al.  The Mechanism of Allosteric Inhibition of Protein Tyrosine Phosphatase 1B , 2014, PloS one.

[148]  Xin Zhou,et al.  PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains , 2011, Proceedings of the National Academy of Sciences.

[149]  György M. Keserü,et al.  Ensemble Docking into Flexible Active Sites. Critical Evaluation of FlexE against JNK-3 and beta-Secretase , 2006, J. Chem. Inf. Model..

[150]  G. Krishnamurthy Rajanikant,et al.  Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors , 2014, Journal of Computer-Aided Molecular Design.

[151]  J. Dixon,et al.  UBLCP1 is a 26S proteasome phosphatase that regulates nuclear proteasome activity , 2011, Proceedings of the National Academy of Sciences.